Literatur
-
1
Andersson J, Sjogren H, Meis-Kindblom J M, Stenman G, Aman P, Kindblom L G.
The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors.
Am J Pathol.
2002;
160
15-22
-
2
Bauer S, Corless C L, Heinrich M C. et al .
Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT.
Cancer Chemother Pharmacol.
2003;
51
261-265
-
3
Blanke C D, von Mehren M, Joensuu H. et al .
Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTs) expressing C-KIT (CD117).
Proc Am Soc Clin Oncol.
2001;
20
1a
-
4
Burkill G J, Badran M, Al-Muderis O. et al .
Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread.
Radiology.
2003;
226
527-352
-
5
Dagher R, Cohen M, Williams G. et al .
Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
Clin Cancer Res.
2002;
8
3034-3048
-
6
De Matteo R P, Lewis J J, Leung D. et al .
Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival.
Ann Surg.
2000;
231
51-58
-
7
Demetri G D, von Mehren M, Blanke C D. et al .
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
N Engl J Med.
2002;
347
472-480
-
8
de Pas T, Casali P G, Toma S. et al .
Gastrointestinal stromal tumors: should they be treated with the same systemic chemotherapy as other soft tissue sarcomas?.
Oncology.
2003;
64
186-188
-
9
Emory T S, Sobin L H, Lukes L, Lee D H, O’Leary T J.
Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site.
m J Surg Pathol.
1999;
23
82-87
-
10
Fletcher C D, Jules J B, Corless C. et al .
Diagnosis of gastrointestinal Stromal Tumors: A Consensus Approach.
Hum Pathol.
2002;
33
459-465
-
11
Heinrich M C, Rubin B P, Longley B J. et al .
Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations.
um Pathol.
2002;
33
484-495
-
12
Hirota S, Isozaki K, Moriyama Y. et al .
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.
Science.
1998;
279
577-580
-
13
Hotfilder M, Lanvers C, Jurgens H, Boos J, Vormoor J.
c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).
ancer Chemother Pharmacol.
2002;
50
167-169
-
14
Joensuu H, Roberts P J, Sarlomo-Rikala M. et al .
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
N Engl J Med.
2001;
344
1052-1056
-
15
Kindblom L G, Remotti H E, Aldenborg F, Meis-Kindblom J M.
Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal.
Am J Pathol.
1998;
152
1259-1269
-
16
Miettinen M, Majidi M, Lasota J.
Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review.
Eur J Cancer.
2002;
38
S39-51
(Suppl 5)
-
17
Miettinen M, Kopczynski J, Makhlouf H R. et al .
Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases.
Am J Surg Pathol.
2003;
27
625-641
-
18
Pierie J P, Choudry U, Muzikansky A, Yeap B Y, Souba W W, Ott M J.
The effect of surgery and grade on outcome of gastrointestinal stromal tumors.
Arch Surg.
2001;
136
383-389
-
19
Roberts P J, Eisenberg B.
Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease.
ur J Cancer.
2002;
38
S37-38
(Suppl 5)
-
20
Rubin B P, Singer S, Tsao C. et al .
KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.
Cancer Res.
2001;
61
8118-8121
-
21
Singer S, Rubin B P, Lux M L. et al .
Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors.
J Clin Oncol.
2002;
20
3898-3905
-
22
Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T. et al .
Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors.
Cancer Res.
1999;
59
4297-4300
-
23
Van den Abbeele A D, Badawi R D.
Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs).
Eur J Cancer.
2002;
38
S60-65
(Suppl 5)
-
24
van Oosterom A T, Judson I, Verweij J. et al .
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.
Lancet.
2001;
358
1421-1423
-
25
van Oosterom A T, Judson I R, Verweij J. et al .
Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group.
Eur J Cancer.
2002;
38
S83-87
(Suppl 5)
Dr. Marcus Schlemmer
Medizinische Klinik und Poliklinik III - Grosshadern, Ludwig-Maximilians-Universität München
Marchioninistraße 15
81377 München
Email: Marcus.Schlemmer@med3.med.uni-muenchen.de
